Outcomes researcher moves south to national nonprofit

Share this article:
Dave Davis, MD, the University of Toronto academic widely respected for his research on outcomes-oriented education, will join the Washington, DC-based Association of American Medical Colleges.

Davis will assume a new position for this nonprofit association—VP, continuing health
education and physician performance improvement in the division of med ed. AAMC oversees several initiatives aimed at improving med ed.

Davis, who currently leads the University of Toronto CME program, said he will work to up awareness of CME, its effectiveness and linkages to the health system. “To have an opportunity at the end of my career to spend time with colleagues who I value in CME across the nation is just a wonderful opportunity,” Davis told MM&M.

The announcement follows part of a sabbatical year Davis spent at AAMC.

ACCME’s updated compliance criteria also prompted the move. “It made me think some of these goals might be attained,” Davis said.

Davis’ current duties have included overseeing a knowledge translation program endowed by Li Ka Shing at Toronto’s St. Michael’s Hospital. He earlier created a CE division at Canada’s McMaster University. Davis said that, in some medical schools, QI in patient care and CME are not meshed well. “Clearly we need to bring those two dimensions together.”

He will begin his new post in late summer or fall as soon as he winds down his medical practice.
Davis will report to Carol Aschenbrener, MD, AAMC EVP.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...